» Articles » PMID: 33224694

Impact of Pharmacists on Outcomes for Patients with Psychiatric or Neurologic Disorders

Overview
Specialty Psychiatry
Date 2020 Nov 23
PMID 33224694
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015.

Methods: A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included.

Results: A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team.

Discussion: Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.

Citing Articles

Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review.

Hernandez Bustamante P, Charles A, Snider M, Catanzano S Ment Health Clin. 2025; 15(1):17-24.

PMID: 39974754 PMC: 11835365. DOI: 10.9740/mhc.2025.02.017.


Effectiveness of a pharmacist-led tele-psychiatric clinic in managing drug-related problems.

Al Shakhori M, Arain S, Abdulsalim S, Salim Karattuthodi M, Al Dhamen M, Almutairi S J Pharm Policy Pract. 2025; 18(1):2460038.

PMID: 39931673 PMC: 11809177. DOI: 10.1080/20523211.2025.2460038.


Clinical pharmacist recommendations in daily interdisciplinary ward rounds at a psychiatric hospital: a retrospective pre-post study on drug-related problems focused in somatic comorbidities.

Stuhec M, Gazdag A, Cuk Z, Oravecz R, Batinic B Front Psychiatry. 2025; 15:1473832.

PMID: 39758448 PMC: 11695304. DOI: 10.3389/fpsyt.2024.1473832.


Prevalence and solving strategies of drug-related problems in adult psychiatric inpatients - a systematic review.

Wien K, Reissner P, Hefner G, Thern J, Borgwardt S Front Psychiatry. 2024; 15:1460098.

PMID: 39698211 PMC: 11652846. DOI: 10.3389/fpsyt.2024.1460098.


Standardized reporting on studies of psychiatric pharmacist interventions.

Parmentier B, Lister J, Moore T, Reinstatler K, Santos R, Payne G Ment Health Clin. 2024; 14(4):271-276.

PMID: 39104438 PMC: 11298031. DOI: 10.9740/mhc.2024.08.271.


References
1.
van Velthuijsen E, Zwakhalen S, Pijpers E, van de Ven L, Ambergen T, Mulder W . Effects of a Medication Review on Delirium in Older Hospitalised Patients: A Comparative Retrospective Cohort Study. Drugs Aging. 2018; 35(2):153-161. PMC: 5847150. DOI: 10.1007/s40266-018-0523-9. View

2.
Harms M, Haas M, Larew J, DeJongh B . Impact of a mental health clinical pharmacist on a primary care mental health integration team. Ment Health Clin. 2018; 7(3):101-105. PMC: 6007568. DOI: 10.9740/mhc.2017.05.101. View

3.
De Hert M, Correll C, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I . Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011; 10(1):52-77. PMC: 3048500. DOI: 10.1002/j.2051-5545.2011.tb00014.x. View

4.
Hannou S, Voirol P, Pannatier A, Weibel M, Sadeghipour F, von Gunten A . Pharmacist intervention acceptance for the reduction of potentially inappropriate drug prescribing in acute psychiatry. Int J Clin Pharm. 2017; 39(6):1228-1236. DOI: 10.1007/s11096-017-0513-8. View

5.
Dimitropoulos E, Bertucci S, Wong K . Integration of a clinical pharmacy specialist into a substance use disorder intensive outpatient treatment program to improve prescribing rates of alcohol use disorder pharmacotherapy. Subst Abus. 2018; 39(2):190-192. DOI: 10.1080/08897077.2018.1449172. View